FDA moves BPC-157 to Category 1 by…?

FDA moves BPC-157 to Category 1 by…?

$5K volume·до Jan 1, 2027
OUTCOMESPROBABILITY · PRICE
December 31, 2026$3K volume01234567890123456789%-4 pp
PriceSharesTotal

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

✓Market open for trading
Proposed outcome
Final review
Questions and answers

“FDA moves BPC-157 to Category 1 by…?” is a prediction market on Melbo. A share’s price reflects the probability of the outcome: on the correct outcome each share settles at $1, on the wrong one at $0.

FDA moves BPC-157 to Category 1 by…? · Melbo